For patients with bladder cancer, invisible blood in urine may aid diagnosis
the ONA take:
According to new research published in the British Journal of General Practice, invisible blood in the urine may be able to be used to diagnose bladder cancer. Researchers at the University of Exeter Medical School in Exeter, United Kingdom, identified over 26,000 patients from the Clinical Practice Research Datalink and found that one in 60 patients over the age of 60 who had invisible blood in their urine were later diagnosed with bladder cancer.
The best known indicator of bladder cancer is visible blood in urine. Identifying invisible blood could boost early detection of bladder cancer, thereby improving outcomes compared with those who are diagnosed late.
According to the National Cancer Institute, if diagnosed with stage 1 bladder cancer, a patient has an 88% 5-year survival rate, but if diagnosed with stage 4 cancer, the 5-year survival rate drops to 15%.
The American Cancer Society says that nearly 75,000 Americans will be diagnosed with bladder cancer and about 16,000 will die from the disease in 2014. Bladder cancer is about three times more likely in men than women and occurs mainly in older adults.
Invisible blood in the urine may be able to be used to diagnose bladder cancer.
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.
The figure was around half those who had visible blood in their urine - the best known indicator of bladder cancer. However, it was still higher than figures for other potential symptoms of bladder cancer that warrant further investigation.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|